Advertisement

memo - Magazine of European Medical Oncology

, Volume 11, Issue 4, pp 305–308 | Cite as

The impact of surgery in oligometastatic prostate cancer

  • Jasmin Bektic
  • Wolfgang Horninger
short review
  • 18 Downloads

Summary

Oligometastatic prostate cancer has been considered an intermediate state between localized disease and widespread metastases, but there is no consensus on the definition of oligometastasis in prostate cancer. At present, a clinical diagnosis made on the basis of up to five extrapelvic lesions is reasonable for use. Retrospective studies and post hoc analyses suggest that local or metastasis-directed interventions could have benefits in the oligometastatic state including a better response to systematic therapy, lower risk of local complications, and possible positive impact on cancer-specific survival and overall survival; however, insufficient data are available to draw reliable conclusions. In this short review, we summarize the current available data on the role of surgery in oligometastatic prostate cancer.

Keywords

Oligometastatic prostate cancer Radical prostatectomy Local therapy Metastasis-directed therapy 

Abbreviations

PCa

Prostate cancer

RP

Radical prostatectomy

mCRPC

Metastastic castration-refractory prostate cancer

ADT

Androgen-deprivation therapy

OS

Overall survival

CSS

Cancer specific survival

PCSM

Prostate cancer specific mortality

Notes

Conflict of interest

J. Bektic and W. Horninger declare that they have no competing interests.

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel era”: data from 917 patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–38.CrossRefPubMedGoogle Scholar
  3. 3.
    Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.CrossRefPubMedGoogle Scholar
  4. 4.
    Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14(1):15–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Ost P, Jereczek-Fossa BA, As NV, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69(1):9–12.CrossRefPubMedGoogle Scholar
  6. 6.
    Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52(8):1622–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Ahmed KA, Barney BM, Davis BJ, et al. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2012;2:215.CrossRefPubMedGoogle Scholar
  8. 8.
    Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.CrossRefPubMedGoogle Scholar
  9. 9.
    Sridharan S, Steigler A, Spry NA, et al. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol. 2016;121(1):98–102.CrossRefPubMedGoogle Scholar
  10. 10.
    Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004;58(1):3–10.CrossRefPubMedGoogle Scholar
  11. 11.
    Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.CrossRefPubMedGoogle Scholar
  12. 12.
    Maurer T, Eiber M, Schwaiger M, et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226–35.CrossRefPubMedGoogle Scholar
  13. 13.
    Aus G, Hugosson J, Norlen L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol. 1995;154(2 Pt 1):466–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Patrikidou A, Brureau L, Casenave J, et al. Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome. Urol Oncol. 2015;33(5):202 e9–202 e17.CrossRefGoogle Scholar
  15. 15.
    Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315–26.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64(6):2205–11.CrossRefPubMedGoogle Scholar
  17. 17.
    Tzelepi V, Efstathiou E, Wen S, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011;29(18):2574–81.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Temple LK, Hsieh L, Wong WD, et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004;22(17):3475–84.CrossRefPubMedGoogle Scholar
  19. 19.
    Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.CrossRefPubMedGoogle Scholar
  20. 20.
    Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.CrossRefPubMedGoogle Scholar
  21. 21.
    Ghavamian R, Bergstralh EJ, Blute ML, et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol. 1999;161(4):1223–7. discussion 7–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Thompson IM, Tangen C, Basler J, et al. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 2002;168(3):1008–12.CrossRefPubMedGoogle Scholar
  23. 23.
    Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058–66.CrossRefPubMedGoogle Scholar
  24. 24.
    Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66(3):602–3.CrossRefPubMedGoogle Scholar
  25. 25.
    Engel J, Bastian PJ, Baur H, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010;57(5):754–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Moschini M, Briganti A, Murphy CR, et al. Outcomes for patients with clinical lymphadenopathy treated with radical prostatectomy. Eur Urol. 2016;69(2):193–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Won AC, Gurney H, Marx G, et al. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 2013;112(4):E250–E5.CrossRefPubMedGoogle Scholar
  28. 28.
    Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193(3):832–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Jang WS, Kim MS, Jeong WS, et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? BJU Int. 2018;121(2):225–31.CrossRefPubMedGoogle Scholar
  30. 30.
    Yao HH, Hong M, Corcoran NM, et al. Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia Pac J Clin Oncol. 2014;10(4):308–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Chao DH, Higgins JP, Brooks JD. Biochemical remission after resection of prostate cancer lung metastasis. Urology. 2004;63(3):584–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of UrologyMedical University of InnsbruckInnsbruckAustria

Personalised recommendations